PresidentMr. Glenn SaldanhaChairman & Managing Director, Glenmark Pharmaceuticals Limited
Mr. Glenn Saldanha is the Chairman & Managing Director of Glenmark Pharmaceuticals Ltd. He joined in 1998 as Director and took over as Managing Director & CEO in 2001.
As Chairman & Managing Director of the Company, Mr. Saldanha oversees all operations of the organization. During his tenure, he transformed Glenmark into a truly global organization with revenue in excess of Rs 9000 crores (USD 1.4 billion) and offices in more than 40 countries worldwide. Under his leadership, Glenmark has evolved from an Indian branded generics business, into a research-driven and innovation-led organization. Mr. Saldanha's vision is to discover, develop and take to market India's first innovative drug for the entire world.
Mr. Saldanha holds a bachelor's degree in pharmacy from Mumbai University and is an MBA from the Leonard Stern School of Business at New York University. Prior to Glenmark, he has worked with Eli Lily, USA and PriceWater House Coopers, USA.
Dr Rajesh Jain
Joint Managing Director, Panacea Biotec
Dr. Rajesh Jain is Joint Managing Director of Panacea Biotec, a leading Biotechnology Company employing over 2,500 people. He provides strategic leadership, management and guidance to the company. He has extensive experience and qualifications in biotechnology and is responsible for Innovation and Business Development.
Dr Jain is an active member of major industry associations and government panels. He is a Co-Chair Confederation of Indian Industry (CII), National Committee on Biotechnology for 2017-18. He is a member of Central Drug Research Institute (CDRI), Lucknow. Dr Jain is a recipient of many awards such as India Innovation Award for 2016 and 2015 by Clarivate Analytics and has been appreciated by GAVI and Bill and Melinda Gates Foundation for his commitment towards making affordable vaccines for population across the globe.
Dr Jain is a science graduate and holds a PhD in Management. He has authored two position papers for CII: Guideline Changes in Vaccine Approval Procedures and Regulatory & Policy Changes for Sustained Competitiveness of the Indian Vaccine Industry.
Mr. Sudarshan Jain
Indian Pharmaceutical Alliance
Sudarshan has a strong passion for healthcare and the education sector. Currently, he is the Secretary-General of the Indian Pharmaceutical Alliance, Advisor - Apax Partners and Board member of multiple organizations. He has served in several leadership positions for over 40 years in Healthcare industry (Lupin, Johnson & Johnson, Piramal, Abbott) and was formerly the Managing Director at Abbott Healthcare Solutions.
His current Board engagements include Abbott India, Healthium Limited (Apax portfolio company), Zandu Chemicals Limited, PharmEasy, Indian Institute of Health Management Research - Jaipur, Indian Education Society (IES), Advisory Board of Narsee Monjee University, Mumbai (NMIMS). He is the Visiting Faculty at Indian Institute of Management (IIM), Ahmedabad. He has contributed in shaping the healthcare policy and improving access to healthcare in India.
Sudarshan is an Alumnus of St. Stephens College, Delhi University and Indian Institute of Management (IIM), Ahmedabad.